AbCellera Announces $28M Upfront Vertex Collaboration On Multispecific T-Cell Engagers For Autoimmune Diseases, Eligible For Milestone Payments And Tiered Royalties
Share
Why It Matters
AbCellera and Vertex are working together on new medicine to fight autoimmune diseases, and AbCellera gets $28 million upfront plus more money if things go well. This shows other companies believe in AbCellera's science, which is a sign the company might be on to something promising.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.